Synlogic Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Synlogic is pioneering the development of a novel class of living treatments, Synthetic BioticTM medicines, based on its proprietary drug development platform. Synlogic's initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit synlogictx.com.
No news available
Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.
